Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Receives Average Rating of “Reduce” from Analysts

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) has received an average rating of “Reduce” from the ten analysts that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation and nine have given a hold recommendation to the company.

BAYRY has been the subject of a number of research reports. Citigroup reissued a “neutral” rating on shares of Bayer Aktiengesellschaft in a research note on Thursday, February 29th. The Goldman Sachs Group initiated coverage on shares of Bayer Aktiengesellschaft in a report on Thursday, May 30th. They issued a “neutral” rating for the company. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Bayer Aktiengesellschaft in a research note on Thursday, March 7th.

Bayer Aktiengesellschaft Stock Performance

BAYRY opened at $6.97 on Friday. The company’s 50-day simple moving average is $7.48 and its two-hundred day simple moving average is $7.89. Bayer Aktiengesellschaft has a 52-week low of $6.89 and a 52-week high of $14.70. The company has a debt-to-equity ratio of 1.06, a quick ratio of 0.87 and a current ratio of 1.31.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last posted its quarterly earnings data on Tuesday, May 14th. The company reported $0.77 earnings per share (EPS) for the quarter. The company had revenue of $14.95 billion for the quarter. Bayer Aktiengesellschaft had a negative net margin of 6.70% and a positive return on equity of 17.57%. On average, research analysts forecast that Bayer Aktiengesellschaft will post 1.36 EPS for the current year.

Bayer Aktiengesellschaft Cuts Dividend

The company also recently declared a dividend, which was paid on Monday, May 13th. Stockholders of record on Tuesday, April 30th were paid a $0.0191 dividend. The ex-dividend date of this dividend was Monday, April 29th. Bayer Aktiengesellschaft’s dividend payout ratio is presently -2.30%.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.